Neoplasms by Site: Clinical Trials

31293 completed, 12349 unknown, 10784 recruiting, 6662 terminated. 23945 Phase 2, 16706 Not applicable, 11996 Phase 1, 6865 Phase 3, 1303 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	23945	Completed 9962, Unknown 3600, Recruiting 3228, Terminated 3140, Active not recruiting 1638, Not yet recruiting 1217, Withdrawn 1021, Suspended 94, Enrolling by invitation 45
Not applicable	16706	Completed 7121, Unknown 3121, Recruiting 2751, Not yet recruiting 1058, Terminated 959, Active not recruiting 940, Withdrawn 560, Enrolling by invitation 138, Suspended 58
Phase 1	11996	Completed 5553, Terminated 1837, Recruiting 1646, Unknown 1107, Active not recruiting 846, Withdrawn 534, Not yet recruiting 367, Suspended 84, Enrolling by invitation 22
Phase 3	6865	Completed 2887, Unknown 1166, Recruiting 1022, Active not recruiting 667, Terminated 637, Not yet recruiting 287, Withdrawn 165, Suspended 22, Enrolling by invitation 12
Phase 4	1303	Completed 595, Unknown 294, Recruiting 139, Terminated 103, Not yet recruiting 86, Withdrawn 37, Active not recruiting 35, Enrolling by invitation 8, Suspended 6
Early Phase 1	1012	Completed 376, Unknown 159, Recruiting 147, Terminated 120, Withdrawn 70, Not yet recruiting 68, Active not recruiting 56, Enrolling by invitation 11, Suspended 5

Follow Neoplasms by Site: new trials by email Literature Review of Neoplasms by Site trials Research Report on Neoplasms by Site

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications	Phase 2	Withdrawn	Institut Paoli-Calmettes		2032-01-01	2026-10-14
9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma 9-ING-41, Carboplatin - Salivary Gland Carcinoma, Adenoid Cystic Carcinoma	Phase 2	Withdrawn	Actuate Therapeutics Inc.		2030-12-18	2022-02-22
Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC certepetide, nab-paclitaxel, gemcitabine - Pancreas Cancer, Pancreatic Carcinoma	Phase 1 / Phase 2	Withdrawn	Lisata Therapeutics, Inc.		2030-01-01	2025-06-06
PROstate Cancer Risk Calculator for ACTionable Clinical Decision-making in Nigeria (a) Training and (b) Supported risk assessment - Prostate Cancer, Risk Assessment	Not applicable	Not yet recruiting	Ahmadu Bello University	89	2029-03-01	2026-07-29
A Study Using Brain Stimulation and Behavioral Therapy to Increase Extent of Resection in Low-Grade Gliomas RNS System Implantation - Glioma, Glioma Intracranial	Not applicable	Not yet recruiting	Medical College of Wisconsin	3	2028-08-01	2026-10-13
Artificial Intelligence-assisted Uro-Cam Catheter Assessment System for Diagnosing Bladder Cancer AI Uro-Cam - Bladder Cancer	Not applicable	Not yet recruiting	Chinese University of Hong Kong	60	2028-07-31	2026-07-22
Combined Program of Supervised Physical Exercise and Nutritional Counseling in Ovarian Cancer Patients on Frontline Maintenance Treatment With PARP Inhibitors Exercise and dietary recommendations - Ovarian Cancer	Not applicable	Not yet recruiting	Oncare Madrid	32	2028-05-01	2026-10-08
Mapping Patient Decision-making in Thyroid Cancer Decision navigation tool - Thyroid Cancer	Not applicable	Not yet recruiting	University of California, Los Angeles	50	2028-04-01	2026-07-24
Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease	Phase 1 / Phase 2	Not yet recruiting	Jubilant Therapeutics Inc.	113	2028-04-01	2026-08-07
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer	Phase 1 / Phase 2	Not yet recruiting	CHU de Quebec-Universite Laval	500	2028-03-01	2025-03-30
Adaptive Neoadjuvant Therapy for Esophageal Cancer Neoadjuvant concurrent chemoradiotherapy - Esophageal Carcinoma, Neoadjuvant Therapy	Not applicable	Enrolling by invitation	Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center	43	2028-03-01	2025-05-25
Improving Clinic Delivery of HIV-related Anal Health Services PEACHES 2.0 Implementation Strategies - HIV, Gonorrhea	Not applicable	Not yet recruiting	Albert Einstein College of Medicine	8	2028-02-01	2026-10-13
The Impact of a Patient Decision Aid on Treatment Choices for Patients With an Unexpected Malignant Colorectal Polyp Shared Decision Making using a Patient Decision Aid. - Shared Decision Making, Colonic Polyp	Phase 2	Not yet recruiting	Vejle Hospital	110	2028-02-01	2026-04-30
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer DCE-MRI - Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression		Not yet recruiting	Hao Xu	400	2028-01-01	2026-02-05
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer	Not applicable	Not yet recruiting	FranciscoVeraSerrano	84	2028-01-01	2026-03-17
CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Metastatic Colorectal Cancer CA102N, TAS-102, Bevacizumab - Metastatic Colorectal Cancer	Phase 2	Suspended	Holy Stone Healthcare Co., Ltd	100	2027-12-01	2026-09-18
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer	Phase 1 / Phase 2	Not yet recruiting	RemeGen Co., Ltd.	26	2027-12-01	2026-09-22
Application of Multimodal MRI in Histological Grading and Prognostic Assessment of Rectal Cancer intravoxel incoherent motion magnetic resonance imaging - Rectal Neoplasms, Prognosis		Not yet recruiting	Sichuan Cancer Hospital and Research Institute	400	2027-11-01	2025-12-08
Symptom Management to Improve Completion of Patient-reported Outcome Measures Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm	Not applicable	Not yet recruiting	Henry Ford Health System	78	2027-10-01	2026-07-29
Endoscopic Ultrasound-Guided Pulsed Electric Field Ablation for the Treatment of Pancreatic Neoplasms Clinical Intervention or Procedure, Electronic Health Record Review, Endoscopic Ultrasound-Guided Fine-Needle Aspiration of the Pancreas - Pancreatic Neoplasm, Pancreatic Neuroendocrine Tumor	Not applicable	Enrolling by invitation	Ohio State University Comprehensive Cancer Center	12	2027-10-01	2026-10-13

Showing 20 of 72696. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (13492)  ·  Carcinoma, Non-Small-Cell Lung (7065)  ·  Prostatic Neoplasms (6444)  ·  Colorectal Neoplasms (6107)  ·  Lung Neoplasms (5256)  ·  Pancreatic Neoplasms (3671)  ·  Neoplasms (3376)  ·  Carcinoma, Hepatocellular (3372)  ·  Ovarian Neoplasms (3258)  ·  Melanoma (3199)  ·  Stomach Neoplasms (3164)  ·  Head and Neck Neoplasms (2698)  ·  Neoplasm Metastasis (2433)  ·  Colonic Neoplasms (2376)  ·  Brain Neoplasms (2364)

Broader conditions

Neoplasms (69320)  ·  Digestive System Diseases (21644)  ·  Digestive System Neoplasms (21287)  ·  Neoplasms by Histologic Type (19063)  ·  Skin and Connective Tissue Diseases (17818)  ·  Skin Diseases (17742)  ·  Urogenital Diseases (17002)  ·  Urogenital Neoplasms (16578)  ·  Neoplasms, Glandular and Epithelial (14415)  ·  Gastrointestinal Diseases (14294)  ·  Breast Diseases (14287)  ·  Gastrointestinal Neoplasms (13478)  ·  Genital Diseases (13179)  ·  Respiratory Tract Diseases (12255)

Interventions

Cisplatin (2606)  ·  Carboplatin (2382)  ·  Paclitaxel (2252)  ·  Radiotherapy (1986)  ·  Gemcitabine (1897)  ·  Docetaxel (1811)  ·  pembrolizumab (1761)  ·  Bevacizumab (1757)  ·  Fluorouracil (1564)  ·  Capecitabine (1526)  ·  Oxaliplatin (1373)  ·  Cyclophosphamide (1253)  ·  Nivolumab (1149)  ·  Irinotecan (927)  ·  Leucovorin (916)

Sponsors

National Cancer Institute (NCI) (2030)  ·  M.D. Anderson Cancer Center (1428)  ·  Memorial Sloan Kettering Cancer Center (1072)  ·  Sun Yat-sen University (884)  ·  Fudan University (830)  ·  AstraZeneca (649)  ·  Mayo Clinic (542)  ·  Hoffmann-La Roche (532)  ·  Pfizer (486)  ·  Novartis Pharmaceuticals (482)  ·  Dana-Farber Cancer Institute (466)  ·  University Health Network, Toronto (454)  ·  National Taiwan University Hospital (404)  ·  Eli Lilly and Company (378)  ·  Alliance for Clinical Trials in Oncology (364)

Countries

United States (29046)  ·  China (12517)  ·  France (5922)  ·  Canada (4671)  ·  Italy (4557)  ·  Spain (4083)  ·  United Kingdom (3991)  ·  Germany (3699)  ·  South Korea (3545)  ·  Netherlands (2583)  ·  Belgium (2506)  ·  Taiwan (2345)  ·  Australia (2341)  ·  Japan (1832)  ·  Poland (1701)

Results publications

PMID 37185961, PMID 38979716, PMID 33538338, PMID 37146227, PMID 34037241, PMID 30207593, PMID 31401903, PMID 37407274, PMID 36648215, PMID 41276263, PMID 34350976, PMID 39606939, PMID 19097774, PMID 26808342, PMID 35623069, PMID 38572751, PMID 39863139, PMID 27238653, PMID 35170751, PMID 25057165, PMID 28410911, PMID 29522361, PMID 31150573, PMID 31395089, PMID 32499241, PMID 33337539, PMID 36306483, PMID 12049862, PMID 25667295, PMID 35101941, PMID 40341124, PMID 40443562, PMID 41170811, PMID 15273542, PMID 15496622, PMID 24722180, PMID 32379297, PMID 32450725, PMID 33270906, PMID 34081125, PMID 35588252, PMID 37162250, PMID 39462179, PMID 41698328, PMID 11981766, PMID 19192962, PMID 22473314, PMID 25577718, PMID 25651787, PMID 40207789

NIH funding

2023 (485), 2017 (263), 2025 (260), 2016 (254), 2019 (249), 2018 (232), 2014 (211), 2015 (207), P30CA033572 (198), 2009 (166), U10CA032102 (160), P30CA016672 (153), 2008 (145), P30CA015083 (139), U10CA031946 (135)